Vol.65 No.1 January 2017
Survey of susceptibility of Candida and Aspergillus species to caspofungin in Japan
1)Pharmacovigilance Area, MSD K.K., KITANOMARU SQUARE, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan
2)Medical Affairs, MSD K.K.
Abstract
A post-marketing survey was performed to examine changes in the susceptibility of Candida (510 strains) and Aspergillus (300 strains) species to caspofungin (CPFG) over time. All the species were isolated from specimens obtained from patients with suspected fungal infections who had been treated at Japanese medical facilities between 2012 and 2014. The minimum inhibitory concentrations (MICs) for the Candida spp. and the Aspergillus spp. were determined using broth microdilution methods according to the standards of the Clinical and Laboratory Standards Institute (M27-A3 and M38-A2, respectively). The CLSI M27-S3 criteria for interpreting susceptibility were used in this study.
The MIC90 value of CPFG against Candida albicans strains isolated in 2012, 2013 and 2014 were 0.25, 0.25 and 0.5 μg/mL, respectively, while the geometric means of CPFG were 0.14, 0.14 and 0.21 μg/mL, respectively. The MIC90 and geometric means for Candida parapsilisis, Candia glabrata, Candida tropicalis, Candida guilliermondii and Candida krusei as well as those for Aspergillus species including Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger and Aspergillus terreus were within the range of double the value for the period. Moreover, no unsusceptible strain with a CPFG MIC of over 2 μg/mL, which is the breakpoint for Candida spp., were observed. These results indicated that the susceptibility of Candida spp. and Aspergillus spp. to CPFG did not decrease the period of 2012 to 2014.
Key word
caspofungin, Candida, Aspergillus, antifungal susceptibility
Received
July 8, 2016
Accepted
October 4, 2016
Jpn. J. Chemother. 65 (1): 17-26, 2017
